Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to esketamine (S-ketamine), since it might be free of psychotomimetic side effects. Using [ 11 C]raclopride and positron emission tomography (PET), we investigated whether esketamine and R-ketamine can affect dopamine D 2/3 receptor binding in the conscious monkey brain. A single infusion of esketamine (0.5 mg/kg), but not R-ketamine (0.5 mg/kg), caused a reduction of binding availability of dopamine D 2/3 receptor in the monkey striatum. This study suggests that unlike to R-ketamine, esketamine can cause dopamine release in the striatum, and that its release might be associated with psychotomimetic effects of esketamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Effect of esketamine and R-ketamine on the BPND of [11C]raclopride to dopamine D2/3 receptors in the striatum of conscious monkeys. a Representative photomicrographs of typical MRI and parametric PET images of [11C]raclopride to dopamine D2/3 receptors from vehicle (saline)-treated, esketamine (0.5 mg/kg, 40-min)-treated and R-ketamine (0.5 mg/kg, 40-min)-treated monkeys. PET images from 61 to 91 min were obtained. Color bar indicates a level of the non-displaceable binding potential (BPND) of [11C]raclopride. b The non-displaceable binding potential BPND of [11C]raclopride in the striatum. The data show the mean ± S.E.M. (n = 4). **P < 0.01 compared with vehicle (saline)-treated condition](https://figures.cochat.ai/paper-figures/20e6477afd9f436cbcaea3029ca73a7b/reduction-of-dopamine-d2-3-receptor-binding-in-the-striatum-after-a-single-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In animal studies, R-ketamine has been reported to have a rapid onset of antidepressant effects and a better side-effect profile than esketamine34–41”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Self-citationKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Domino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
Cited by
Items 101–129 of 129
Ketamine in Clinical Practice: Transitioning from Anesthetic Agent to Psychiatric Therapeutic
Quintero, J.-M., Bustos, R., Lechtig, S., Beltran, S., & Zarate, C. A. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009585330.007 · Cited by 13
Lin, G., Xu, Q., Li, J., Chu, Z., Ma, X., Zhu, Q., Zhao, Y., Mo, J., Ye, W., Shao, L., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01524 · Cited by 13
Guan, Y., Pan, H., Cong, X., Fang, F., Du, S., Wang, X., Ding, Y., Zhou, Y., & Yu, S. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16165 · Cited by 12
Ma, L., Eguchi, A., Liu, G., Qu, Y., Wan, X., Murayama, R., Mori, C., & Hashimoto, K. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173736 · Cited by 12
Self-citationZhou, J., Chen, Z., Liu, Y., Zhong, M., Zhong, Q., Wei, J., Hu, Q., Wang, J., & Wang, L. (2024) · CNS Drugs · doi:10.1007/s40263-024-01083-2 · Cited by 13
Ketamine in depression and electroconvulsive therapy
Rozet, I. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001039 · Cited by 10
Esketamine Inhibits Cocaine-Seeking Behaviour Subsequent to Various Abstinence Conditions in Rats
Wydra, K., Witek, K., Suder, A., & Filip, M. (2023) · Biomolecules · doi:10.3390/biom13091411 · Cited by 9
Kale, K. M., Goldstein, P. A., & Pandit, J. J. (2026) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000007888 · Cited by 7
Ketamine reduces temporal expectation in the rhesus monkey
Brulé, S., Herlin, B., Pouget, P., & Missal, M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05706-6 · Cited by 7
Decoding effects of psychoactive drugs in a high-dimensional space of eye movements in monkeys
Liu, X., Cheng, Z., He, L., Tan, J.-X., Chen, W., Bao, Y., Liu, Y., Zhong, L., Yao, Y., Wang, L., et al. (2023) · National Science Review · doi:10.1093/nsr/nwad255 · Cited by 5
Zhang, X., Liu, Y., Xie, W.-X., Mao, Y., Liu, A., Huang, S., Hong, W.-P., Hong, Y.-F., Xu, X., & Chen, Z.-Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115860 · Cited by 4
Antidepressant Actions of Ketamine and Its Two Enantiomers
Chang, L., Wei, Y., & Hashimoto, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_7 · Cited by 4
Self-citationBhavya, Shetty, S., & Sadasivam, B. (2025) · Cureus · doi:10.7759/cureus.91829 · Cited by 3
Luo, X., Zhang, D., Zhang, F., Luo, Q., Huang, K., Liu, X., Yang, N., Li, J., Qiao, W., & Yang, L. (2023) · Journal of Analytical Toxicology · doi:10.1093/jat/bkad021 · Cited by 2
Değirmenci, Ö., Key, E., Mull, D. D., & Gönül, A. S. (2024) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2024.100236 · Cited by 2
Dormegny-Jeanjean, L. C., Lenoir, S., Humbert, I., Mainberger, O., Lozere, C., Meyer, C., Gény, B., Michel, B., Foucher, J., & de Billy, C. D. C. (2025) · Pharmacopsychiatry · doi:10.1055/a-2590-3469 · Cited by 1
Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far
Diendorfer, C., Bum, C., Weidenauer, A., Sauerzopf, U., Bartova, L., Dajic, I., Müller, L., Rujescu, D., Praschak-Rieder, N., & Willeit, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1766485 · Cited by 1
Comparative EEG analysis of the effects of ketamine enantiomers and metabolites in rhesus macaques
Iwamura, Y., Nishigori, K., Yamaguchi, M., Ogi, Y., Kobayashi, A., 岩崎, 剛., Nagata, H., & Ikeda, K. (2026) · Journal of Neurophysiology · doi:10.1152/jn.00203.2025 · Cited by 1
Bærentzen, S. L., Thomsen, J. B., Thomsen, M. B., Jakobsen, S., Simonsen, M. I. T., Wegener, G., Brooks, D. J., & Landau, A. M. (2024) · Synapse · doi:10.1002/syn.22294 · Cited by 1
Linking 5-hydroxytryptamine to antidepressant actions of (R)-ketamine and social stress model
Zhang, K., & Hashimoto, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00056-6
Self-citationEmergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future Directions
Singh, A., & Bedi, P. M. S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.99765
(R)-Ketamine: A New Rapid-Acting Antidepressant
Zhang, K., & Hashimoto, K. (2021) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-79790-4_1 · Cited by 1
Self-citationProgress in Clinical Application of Esketamine in Gynecological Patients
余, 凤. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.132217
Arketamine: Unapproved but Promising Antidepressant with Multiple Brain Benefits
Wan, X., & Hashimoto, K. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_15
Self-citationKetamine toxicity: Translating preclinical findings to adverse effects in humans
Nezic, K., Ntafoulis, I., & Jacobs, G. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00009-6
Ketamiinin vaikutusmekanismit masennuksen hoidossa
Kaikkonen, V. (2024) · UTUPub (University of Turku)
Molecular mechanisms for prophylactic effects of arketamine in inflammation model of depression
Li, M. A. (2023) · Institutional Repositories DataBase (IRDB) · doi:10.20776/900122559
THE IMPACT OF INTRANASAL ESKETAMINE ON TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW
Kotlarski, W., Kotlarska, K. M., Mainka, T. S., & Sergejuk, E. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5523
Metadata
- Authors
- Hashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H.
- Affiliations
- Chiba University (JP)
- Hamamatsu Photonics (Japan) (JP)
- Corresponding author
- Hashimoto, Kenji
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2016-04-18
- Volume
- 267
- Issue
- 2
- Pages
- 173-176
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- PMC
- PMC5323469
- OpenAlex
- W2337679024
- Cited by
- 127
- References
- 19
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 13 · 2023: 10 · 2022: 13 · 2021: 14 · 2020: 19 · 2019: 16 · 2018: 12 · 2017: 11 · 2016: 6
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (24116006)
- Chiba University
- National Institutes of Health
- Japan Society for the Promotion of Science (24116006)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- esketamine, (R)-ketamine, dopamine D2/D3 receptors, striatum, psychotomimetic effects, dopamine release, antidepressants, conscious monkeys
- MeSH terms
- Animals, Antidepressive Agents, Ketamine, Macaca mulatta, Male, Neostriatum, Receptors, Dopamine D2, Positron-Emission Tomography, Receptors, Dopamine D3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.